This article is more than 5 years old. Information may no longer be current.
Stent thrombosis reduced by everolimus-eluting stents
Baber U. J Am Coll Cardiol. 2011;58:1569-1577.
Click Here to Manage Email Alerts
Intracoronary implantation of everolimus-eluting stents vs. non–everolimus-eluting drug-eluting stents yielded highly significant reductions in stent thrombosis, target vessel revascularization and MI, recent study result suggested.
Researchers searched Medline, Scopus, the Cochrane Library and Internet sources and found 13 randomized trials that compared outcomes between everolimus-eluting stents (EES) and non–everolimus-eluting drug-eluting stents (EE-DES). Inclusion criteria for the randomized trials were a randomized comparison between EES and non-EES, reports of clinical outcomes and reports of the frequency of stent thrombosis.
Researchers found reported rates of definite or probable stent thrombosis in all 13 randomized trials, as well as a report of MI in all trials. In the EES group, there was a 0.7% frequency of stent thrombosis, a 5.7% frequency of target vessel revascularization and a 2.9% frequency of MI vs. non–EE-DES. According to study results, EES reduced stent thrombosis (RR=0.55; 95% CI, 0.38-0.78), target vessel revascularization (RR=0.77; 95% CI, 0.64-0.92) and MI (RR=0.78; 95% CI, 0.64-0.96) vs. non–EE-DES, and there was no difference in cardiac mortality (RR=0.92; 95% CI, 0.74-1.16).
 |
Follow CardiologyToday.com on Twitter. |